1 July 2023 updates as part of the Digital Transformation of Authority Required (Written) PBS listings
Page last updated: 1 July 2023
From 1 July 2023 the PBS listings for the medicines outlined in the table below will be updated as part of the Department of Health and Aged Care’s digital transformation of Authority Required (Written) Pharmaceutical Benefits Scheme (PBS) listings. Real time assessment of authority requests for these medicines will be available through Services Australia’s Online PBS Authorities (OPA) system, via Health Professional Online Services (HPOS).
For further information on these changes, please refer to the PBS news item published on 30 June 2022, ‘Digital Transformation of Authority Required (Written) PBS listings’.
The Department of Health and Aged Care is working to update all relevant PBS listings as quickly as possible. Further information will be published on the PBS website as groups of medicines are reviewed.
From 1 July 2023 the PBS listings for the following medicines will be updated
|
Medicine name, Form, Quantity |
PBS item code, Program code |
Indication, Treatment phase |
|---|---|---|
|
eltrombopag 25 mg tablet, 28 |
5825N (HB) |
Severe thrombocytopenia – Initial treatment - New Patient |
|
eltrombopag 25 mg tablet, 28 |
5827Q (HS) |
Severe thrombocytopenia – Initial treatment - New Patient |
|
eltrombopag 50 mg tablet, 28 |
5826P (HB) |
Severe thrombocytopenia – Initial treatment - New Patient |
|
eltrombopag 50 mg tablet, 28 |
5828R (HS) |
Severe thrombocytopenia – Initial treatment - New Patient |
|
romiplostim 250 microgram injection, 1 vial
|
9696H (HB) |
Severe thrombocytopenia – Initial treatment - New Patient |
|
romiplostim 250 microgram injection, 1 vial
|
9697J (HS) |
Severe thrombocytopenia – Initial treatment - New Patient |
|
romiplostim 500 microgram injection, 1 vial
|
9698K (HB) |
Severe thrombocytopenia – Initial treatment - New Patient |
|
romiplostim 500 microgram injection, 1 vial
|
9699L (HS) |
Severe thrombocytopenia – Initial treatment - New Patient |
|
tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL pen devices |
11744D (GE) |
Active giant cell arteritis – Initial treatment |
|
tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL syringes |
11743C (GE) |
Active giant cell arteritis – Initial treatment |
|
tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL pen devices |
11722Y (GE) |
Active giant cell arteritis – Continuing treatment |
|
tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL syringes |
11721X (GE) |
Active giant cell arteritis – Continuing treatment |
